An optimized version of ACI-24, an experimental vaccine designed to induce an immune response against abnormal protein clumps that drive Alzheimer’s disease, was able to induce a powerful immune response — as intended — and generally was well-tolerated in animal studies. Scientists at AC Immune, which is developing ACI-24, published the findings in Brain Communications, in a study titled “An Amyloid-beta (Abeta) vaccine that safely drives immunity to a key pathological species in Alzheimer’s disease:…
You must be logged in to read/download the full post.
The post Optimized Amyloid-targeting Vaccine ACI-24 Shows Promise in Animal Studies appeared first on BioNewsFeeds.